- Home
- UTHR vs FDS Comparison
UTHR vs FDS Comparison
Compare UTHR & FDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- FDS
- Stock Information
- Founded
- UTHR 1996
- FDS 1978
- Country
- UTHR United States
- FDS United States
- Employees
- UTHR N/A
- FDS N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- FDS Computer Software: Programming Data Processing
- Sector
- UTHR Health Care
- FDS Technology
- Exchange
- UTHR Nasdaq
- FDS Nasdaq
- Market Cap
- UTHR 20.7B
- FDS 17.6B
- IPO Year
- UTHR 1999
- FDS 1996
- Fundamental
- Price
- UTHR $437.62
- FDS $265.02
- Analyst Decision
- UTHR Buy
- FDS Hold
- Analyst Count
- UTHR 16
- FDS 10
- Target Price
- UTHR $472.94
- FDS $356.78
- AVG Volume (30 Days)
- UTHR 629.5K
- FDS 833.8K
- Earning Date
- UTHR 10-29-2025
- FDS 12-18-2025
- Dividend Yield
- UTHR N/A
- FDS 1.66%
- EPS Growth
- UTHR 16.08
- FDS 11.79
- EPS
- UTHR 26.38
- FDS 15.55
- Revenue
- UTHR $3,128,400,000.00
- FDS $2,321,748,000.00
- Revenue This Year
- UTHR $13.82
- FDS $6.17
- Revenue Next Year
- UTHR $5.71
- FDS $5.44
- P/E Ratio
- UTHR $16.63
- FDS $17.01
- Revenue Growth
- UTHR 13.50
- FDS 5.39
- 52 Week Low
- UTHR $266.98
- FDS $260.00
- 52 Week High
- UTHR $479.50
- FDS $499.87
- Technical
- Relative Strength Index (RSI)
- UTHR 54.98
- FDS 30.48
- Support Level
- UTHR $409.15
- FDS $284.75
- Resistance Level
- UTHR $479.50
- FDS $293.85
- Average True Range (ATR)
- UTHR 13.84
- FDS 8.46
- MACD
- UTHR -0.64
- FDS -0.07
- Stochastic Oscillator
- UTHR 40.46
- FDS 13.64
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for roughly 82% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.